Name (Synonyms) | Correlation | |
---|---|---|
drug479 | Enoxaparin/Lovenox Intermediate Dose Wiki | 0.33 |
drug569 | Heparin Infusion Wiki | 0.33 |
drug1663 | standard protocol Wiki | 0.33 |
drug446 | Duplex ultrasound and Computed Tomography Angiography Wiki | 0.33 |
drug1447 | Unfractionated heparin SC Wiki | 0.33 |
drug1445 | Unfractionated Heparin IV Wiki | 0.33 |
drug426 | Diagnostic examination for venous thromboembolism Wiki | 0.33 |
drug570 | Heparin SC Wiki | 0.33 |
drug1674 | thromboprofylaxis protocol Wiki | 0.33 |
drug474 | Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki | 0.33 |
drug1675 | thromboprophylaxis with low-molecular-weight heparin or fondaparinux Wiki | 0.33 |
drug473 | Enoxaparin 1 mg/kg Wiki | 0.33 |
drug477 | Enoxaparin Prophylactic Dose Wiki | 0.33 |
drug441 | Dose of Tinzaparin or Dalteparin Wiki | 0.33 |
drug331 | Clopidogrel Wiki | 0.24 |
drug472 | Enoxaparin Wiki | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D054556 | Venous Thromboembolism NIH | 0.75 |
D011655 | Pulmonary Embolism NIH | 0.50 |
D020246 | Venous Thrombosis NIH | 0.50 |
D013927 | Thrombosis NIH | 0.46 |
D004617 | Embolism NIH | 0.35 |
D016769 | Embolism and Thrombosis NIH | 0.19 |
D016638 | Critical Illness NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001907 | Thromboembolism HPO | 0.59 |
HP:0002625 | Deep venous thrombosis HPO | 0.45 |
HP:0002204 | Pulmonary embolism HPO | 0.38 |
There are 9 clinical trials
The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an increased hypercoagulable state.
Description: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism
Measure: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism Time: 28 daysDescription: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism
Measure: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism Time: 28 daysThis study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care but determining the dose of anticoagulation is based on physician preference. The investigators are conducting this study (a randomized trial with adaptive design employing cluster randomization) with the support of all of the ICUs to collect data in order to determine what should be the standard of care in terms of anticoagulation in these critically ill patients. The patients care will not be altered other than the choice of anticoagulation (both approved and used throughout the hospital as standard of care) based on the ICU bed they are assigned. Patient data will be collected until discharge.
Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).
Measure: Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU Time: Discharge from ICU or 30 daysDescription: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).
Measure: Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events Time: Discharge from hospital or 30 daysDescription: Length of stay measured in days.
Measure: ICU Length of Stay Time: Discharge from ICU or 30 daysDescription: The impact of intermediate-dose anti-coagulation compared with prophylactic anti-coagulation on rates of acute kidney injury and renal recovery in the ICU will be measured with the total number of patients who need of renal replacement therapy in the ICU.
Measure: Total Number of Patients with the Need for Renal Replacement Therapy in the ICU Time: Discharge from hospital or 30 daysDescription: Major bleeding will be assessed by BARC criteria, also explored by International Society on Thrombosis and Haemostasis (ISTH) and Thrombolysis in Myocardial Infarction (TIMI) criteria.
Measure: Total Number of Patients with Major bleeding in the ICU Time: Discharge from hospital or 30 daysDescription: Length of stay measured in days.
Measure: Hospital Length of Stay Time: Discharge from hospital or 30 daysWorldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.
Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death
Measure: Venous thromboembolism Time: 28 daysDescription: Risk of major bleeding defined by the ISTH
Measure: Major bleeding Time: 28 daysDescription: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH
Measure: Major Bleeding and Clinically Relevant Non-Major Bleeding Time: 28 daysDescription: Risk of Venous Thromboembolism and Major Bleeding
Measure: Net Clinical Benefit Time: 28 days and 2 monthsDescription: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb
Measure: Venous Thromboembolism at other sites Time: 28 daysDescription: Risk of arterial thrombosis at any sites
Measure: Arterial Thrombosis Time: 28 daysDescription: Risk of all-cause mortality
Measure: All-Cause Mortality Time: 28 days and 2 monthsDescription: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF
Measure: Factors associated with the risk of venous thromboembolism Time: 28 daysSevere COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.
Description: Patients with symptomatic pulmonary embolism confirmed on the CT-angiography and those with a swollen limb and confirmed deep venous thrombosis on compression ultrasound were considered to have "symptomatic venous thromboembolisms". The remaining patients with positive limb ultrasound or CT-angiography were considered to have "asymptomatic venous thrombembolism"
Measure: Venous thromboembolisms Time: 7 daysDescription: Deaths from all causes during the follow-up
Measure: Deaths Time: 7 daysThe aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Description: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 2 week mortality Time: 2 weeks after admission at ICUDescription: the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
Measure: incidence of venous thromboembolism Time: during ICU stay up till 3th of May 2020Description: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 1 week mortality Time: 1 week after admission at ICUDescription: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 3 week mortality Time: 3 weeks after admission at ICUDescription: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 1 month mortality Time: 1 month after admission at ICUDescription: incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
Measure: incidence of kidney failure Time: during ICU stay up till 3th of May 2020Description: incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
Measure: incidence of continuous renal replacement therapy (CRRT) Time: during ICU stay up till 3th of May 2020Description: evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
Measure: lowest PaO2/FiO2 (P/F) ratio Time: during ICU stay up till 3th of May 2020Description: evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
Measure: highest Sequential Organ Failure Assessment (SOFA) score Time: during ICU stay up till 3th of May 2020Description: evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
Measure: length of stay Time: during ICU and hospital stay up till 3th of May 2020Description: evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
Measure: highest bilirubin Time: during ICU stay up till 3th of May 2020Description: evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
Measure: highest ( AST Time: during ICU stay up till 3th of May 2020Description: evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
Measure: highest Aspartaat-Amino-Transferase (ALT) Time: during ICU stay up till 3th of May 2020The purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.
The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive care hospitalization and to evaluate the influence of different anticoagulation regimens on these parameters and on the incidence of thromboembolic events
This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT
Measure: Primary endpoint: Venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierDescription: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia
Measure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierThe aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.
Description: 28-days ICU mortality from admission to the ICU. Discontinue of ICU-care to palliative care counts as death.
Measure: 28-days ICU mortality Time: 28 days from ICU-admissionDescription: Thromboembolic events are defined as pulmonary emboli (PE), deep venous thrombus (DVT), ischemic stroke and other peripheral arterial emboli. PE is defined as PE verified by computer tomography or by findings of acute strain of the right heart on echocardiography combined with a clinical interpretation of the patients deteriorating as a probable PE stated in the medical records. DVT is defined as DVT verified with ultrasound. Ischemic stroke is defined as ischemic stroke verified by computer tomography. Peripheral arterial emboli are defined as peripheral arterial emboli verified by computer tomography.
Measure: Incidence of thromboembolic events Time: 28 days from ICU-admissionDescription: The event of bleeding will be defined by WHO modified bleeding scale as 1-4.
Measure: Incidence of bleeding events Time: 28 days from ICU-admissionDescription: ICU-free days alive during 28 days from ICU-admission. Counts as 0 days if discharged to ward for palliative treatment.
Measure: ICU-free days alive from ICU-admission. Time: 28 days from ICU-admissionDescription: D-dimer every day it is measured during first 28 days from ICU-admission.
Measure: D-dimer levels in the three groups groups Time: 28 days from ICU-admission